On June 23, 2025, Cidara Therapeutics reported positive results from its Phase 2b NAVIGATE trial for CD388, showing up to 76.1% efficacy in preventing seasonal influenza in adults, with no serious safety concerns. The company plans to discuss these results further with the FDA and will hold a conference call on the same date to provide more updates.